Journal of Urologic Oncology

Search

Page Path

Prostate Cancer

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials: Matthew Rashid, Eli Oldham, Griffin K. Hughes, Andriana M. Peña, Chase Ladd, Brooke Gardner, Ryan McIntire, Bradley Johnson, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar; Journal of Urologic Oncology. 2024;22(3):211-223. Published online November 30, 2024; DOI: https://doi.org/10.22465/juo.244800520026
Cited By 1; Full text PubReader ePub PDF

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043

MOST READ MOST CITED

6,014	New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer
5,489	The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
4,998	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
4,833	Complex Epidemiology of Prostate Cancer in Asian Countries
4,687	The Present and Future of Intravesical Therapy in Bladder Cancer

Cited By 9	Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Cited By 4	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
Cited By 4	Complex Epidemiology of Prostate Cancer in Asian Countries
Cited By 3	The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Cited By 2	Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use

Editorial Office: Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817, FAX: +82-2-742-4665 Email: journal@e-juo.org

Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail: kspe.editor@gmail.com